# An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis

> **NCT02321306** · PHASE2 · WITHDRAWN · sponsor: **Mirum Pharmaceuticals, Inc.**

## Conditions studied

- Primary Biliary Cirrhosis

## Interventions

- **DRUG:** LUM001

## Key facts

- **NCT ID:** NCT02321306
- **Lead sponsor:** Mirum Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-05
- **Primary completion:** 2017-12
- **Final completion:** 2018-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study stopped early, before enrolling its first participant.
- **Last updated:** 2019-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02321306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02321306, "An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02321306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*